The cytokinesis-block micronucleus technique and its application to genotoxicity studies in human populations. by Fenech, M
Environmental Health Perspectives Supplements
Vol. 101 (Suppl. 3): 101-107 (1993)
The Cytokinesis-Block Micronucleus
Technique and Its Application to Genotoxicity
Studies in Human Populations
by Michael Fenech
The development of the cytokinesis-block (CB) technique has made the human lymphocyte micronucleus
assay (MN) areliable andprecise method forassessing chromosome damage. Recent studies in ourlaboratory
have confirmed that this method is a sensitive indicator ofin vivo radiation exposure in patients undergoing
fractionated partial-bodyradiotherapy androdents exposedtouniformwhole-body irradiation, thus support-
ing the application ofthe cytokinesis-block micronucleus (CBMN) assay for biological dosimetry. To further
define the use of this assay in biomonitoring, we have also undertaken extensive studies to determine the
spontaneous level ofMN in normal humanpopulations and its relationshiptovarious lifestyle factors. During
the past year, we have also developed a new variation to the CBMN assay that enables the conversion of
excision-repairable lesions to MNwithin one cell-cycle usingcytosine arabinoside.Withthis methodtheslope
of the in vitro dose-response curves was increased by a factor of 1.8 for X-rays, 10.3 for ultraviolet (254 nm)
radiation, and approximately 40-fold for methylnitrosourea. Consequently, the CBMN assay can now be used
not only to measure whole chromosome loss or chromosome breaks but also excision repair events. The
versatility and simplicity ofthe CBMN assaytogetherwith new developments in automation should enable its
successful application inmonitoringexposedpopulations aswell as identifyingmutagen-sensitive individuals
within a population.
Introduction
The level of genetic integrity of human populations is
increasingly under threat due to industrial activities that
result in exposure to chemical and physical genotoxins.
Other factors that can influence genetic damage include
lifestyle factors (e.g., diet), various medical therapies, and
climatic changes (e.g., increased exposure to ultravoilet
radiation due to depletion of atmospheric ozone). It is
therefore important to be able to a) determine what is an
acceptable level ofgenetic damage in a human population,
b) identify individuals who could be hypersensitive to
selected genotoxins, c) effectively screen new chemicals
that are released into the environment, d) determine the
level of increase in genetic damage in a population fol-
lowing a major accident, and e) routinely monitor indi-
viduals who are occupationally exposed to agents that can
be detrimental at the genetic level.
A number of methodologies have been developed over
the past 20 years, varying from cytogenetic techniques
that can give a broad assessment of mutagenic events to
adduct assays that are designed to detect exposure to
specific agents. No one technique can satisfy all the
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requirementsidentified above, and itis nowrealized that a
varietyofmethods canbecombined toprovide aneffective
screening system (1,2).
As part of our effort in this area of research, we have
been actively involved in the development ofmicronucleus
(MN) assays in human lymphocytes to measure both
whole chromosome loss and chromosome breaks (Fig. 1).
The MN methodology is simple and allows rapid assess-
ment of cells, thus making it an economical procedure to
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FIGURE 1. Micronucleus in a dividing nucleated cell. Micronuclei origi-
nate from either lagging chromosomes or chromosome fragments at
anaphase. Micronuclei are readily identified because they are mor-
phologically identical to but smaller than the main nuclei. A nondividing
cell is unable to express its chromosome damage as micronuclei. Cells
that have completed one nuclear division can be accumulated and identi-
fied as binucleate cells by adding cytochalsin-B, a cytokinesis blocking
agent (3,4). Micronuclei are then scored in binucleated cells only.M. FENECH
implement on a large scale. MN assays can only be effec-
tive as quantitative biological dosimeters ifone can iden-
tify those cells that have divided after exposure because
only dividing cells can express micronuclei. This goalwas
achieved by the development of the cytokinesis-block
micronucleus (CBMN) technique, which uses cytochala-
sin-B to stop dividing cells from performing cytokinesis,
thus allowing cells that have completed one nuclear divi-
sion to berecognized bytheirbinucleate appearance (3,4).
As aconsequence, the CBMN assayhasbeen showntobe
more accurate and more sensitive than the conventional
methods that do not distinguish between dividing and
nondividing cells (4,5). The development of the CBMN
assayhas enabled directandvalid comparisonswithchro-
mosome aberration assays. It has now been shown con-
clusivelythatthe CBMN assaycan detectbetween 60 and
90% of acentric fragments (6,7), although the relative
efficiency specific for chromatid deletions as opposed to
chromosome deletionshasyettobedefined. Furthermore,
the CBMN assay combined with kinetochore or cen-
tromere detection has been shown to be an optimal pro-
cedure for measuring whole chromosome loss events (8-
10). Further technical developments (e.g., chromosome
painting) may also allow the measurement of unequal
distribution of chromosomes within daughter nuclei in
cytokinesis-blocked binucleate cells. The scope for using
the CBMN method in human population monitoring and
recent advances in methodology are discussed below.
Spontaneous Micronucleus
Frequencies in Human Populations
Spontaneous or baseline MN frequencies in cultured
human lymphocytes provide an index of accumulated
genetic damage occurring during the lifespan ofcirculat-
ing lymphocytes. The half-life and mean lifespan oflong-
livedT-lymphocyteshasbeenestimatedtobe3yearsand4
years,respectively(11,51).Theobservedgeneticinstability
may also reflect accumulated mutations in the stem cell
lineage fromwhich the mature lymphocytes originate.
The type of mutations that could contribute to spon-
taneous micronuclei include a) mutations to kinetochore
proteins, centromeres, and spindle apparatus that could
leadtounequalchromosome distributionorwholechromo-
some loss at anaphase, and b) unrepaired DNA strand
breaksinducedendogenouslyorasaresultofenvironmen-
tal mutagens, which may result in acentric chromosome
fragments. Studies using kinetochore antibodies to iden-
tify whole chromosomes suggest that approximately 50%
of spontaneously occurring micronuclei are the conse-
quenceofwholechromosomelossandtherestarepresum-
ably derived from acentric chromosome fragments (8-10).
For the purpose of biological dosimetry, the spon-
taneous MN frequency refers to the incidence of MN
observed in the absence of the environmental risk or
exposure that is being assessed. The spontaneous MN
frequency of a population has to be established to deter-
mine acceptable normal values as well as providing base-
line data for those situations when spontaneous MN
frequency for individuals is not known before exposure
(e.g., in large-scale civilian accidents). The population
database should a) enable an estimate ofthe induced MN
frequency (i.e., observedminus expected spontaneous fre-
quency) to be determined after an exposure accident, and
b) given the establishment ofdose-response parameters,
an exposure dose can be calculated. The population
database should span every decade up to 90 years and
includeaminimumof20individualsofeachsexperdecade.
Ideally,thisdatabaseshouldbeupdatedregularly(every2
years) to take into account the possible contribution of
changinglifestyle factors aswell as changesintechnique.
The database should also be used to identify lifestyle
factors that can contribute significantly to the micro-
nucleus index.
During an International Atomic Energy Agency-
sponsored Research Coordination meeting for Radiation
Biological DosimetryheldinRiodeJaneiroinJune1990,it
was agreed that a compilation and comparison ofbaseline
MN frequency data from various countries would be a
useful exercise because it could enable a normal range of
baseline values to be established as well as identify
possible confounding factors. As part ofour effort in this
area, we have been collecting baseline data for the south
Australian population. Our results on 225 individuals
clearly suggest a significant positive correlation of MN
frequency with age (Fig. 2). A comparison of the linear
regression lines formales and females initially suggested
that the slope and intercept for the relation of MN fre-
quency with age was higher in females. Ib determine the
significance ofthis observation and the possible effect of
smoking,multivariate regression analysiswasperformed.
The data set included information on 155 females and 70
males relating to age, sex, and smoking status including
the number ofcigarettes smoked per dayand the number
ofyears smoking. Only29oftheindividualsinthe dataset
weresmokers,andfor69oftheindividuals, noinformation
wasavailableinrelationtosmoking. Initialanalysis,ignor-
ing the contribution of age and smoking, suggested that
females do not have significantly higher MN frequency
counts than males (p>0.20). However, after adjusting for
age, the difference between the MN frequency in males
andfemaleswashighlysignificant(p<0.001).Afteradjust-
ing for age and sex, putting cigarettes in the model indi-
cated thatindividualswith ahighcigarettes/dayratioalso
have significantly elevated MN frequency counts when
compared to low consumers (p<0.02). However, the num-
ber ofyears smoking appeared to have no bearing on the
observedMNfrequency(p>0.20).Otherlaboratoriesusing
the CBMN assay for population monitoring have also
reported significant increments in MN frequency related
to smoking(12,13) andaging(12-15).ThereportsbyYager
et al. (14) and Migliore et al. (15) also show a very good
agreement with the slope of the age-related increase in
MN frequency reported in our studies (4). These data
suggest that the CBMN methodology is reproducible in
different laboratories and sensitive enough to detect the
effects oflifestyle factors.
The study of spontaneous MN frequencies can also be
performed on an individual basis. The spontaneous MN
frequencies in individuals are particularly important in a
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FIGURE 2. Spontaneous micronuclei frequencyincytokinesis-blocked lymphocytes of224healthyAustralians plottedinrelation totheageofthe donor.
The correlation between micronuclei frequency and age is statistically significant (p < 0.0001).
continuous monitoring program of individuals who are
occupationally at risk of exposure to a powerful environ-
mentalmutagensuchasradiation. Inthiscase,individuals
act as their own controls, and their MN frequencies are
measured before and at regular intervals during their
occupation. This situation is ideal because differences in
lifestyle factors should not be a confounding factor. How-
ever,thisapproachisalsodependentonthereproducibility
ofthe assay; in other words, the assay should provide the
same result when measurements are done on the same
individual on separate occasionsbetweenwhich no signifi-
cantexposure tomutagenic agents has occurred. Ourown
studies onbaseline MNfrequenciesincytokinesis-blocked
binucleatelymphocytes of12normalindividualsmeasured
on two occasions 1 year apart show a good correlation
between these measurements [R = 0.845, p < 0.001(16)].
These type ofresults indicate that the CBMN methodol-
ogy is a reliable and predictable method, but the residual
level ofuncertaintyin MN frequencymeasurements should
be taken into account when estimating risk. Furthermore,
the relative incremental risk (RIR) after an exposure, esti-
mated by the ratio ofinduced MN frequency and the spon-
taneous MN frequency, should also be measured because it
accounts for the genetic damage that has already been
accumulated in an individual before exposure due to age,
lifestyle factors, or previous unknown exposure.
Induction of Micronuclei in
Cytokinesis-Blocked Cells after
Exposure to Radiation or Chemicals
Ionizing Radiation
Our own initial in vitro studies with-the CBMN assay
indicated quite clearlythat ifthe baseline frequency ofan
individual was known before exposure, it was possible to
detect increments in MN induction after exposures as low
as0.05Gy(4). Thedetectionlimitcouldbefurtherlowered
ifmore binucleate cells were scored. In view ofthese en-
couragingdata,wehaveevaluatedtheperformanceofthis
assay as an in vivo dosimeter in a recently completed
study on micronucleus induction in cancerpatients under-
going fractionated partial body radiotherapy at different
sites with different irradiated volumes and integral doses
(17). Measurements during radiotherapy have shown a
dose-related increase in MN in all patients studied. The
observed MN frequency correlated significantly (p<0.0001)
with the equivalent body dose, which was estimated by
dividing the integral dose bythe bodyweight. This result
suggests that the redistribution of lymphocytes had
resulted in uniform exposure to the lymphocyte pool. The
regression line for the relationship between equivalent
body dose (X, in Gy) and the MN frequency (Y) is
described by the equation:
Y = 75.8X + 49.5 (R = 0.783)
Furthermeasurementsweremadeperiodicallyup to 12
months after treatment. Taken together, these results
showed ageneraldeclineinMNfrequencywhencompared
to the frequencies at the end oftreatment, decreasing to
91% after 3 months, 72% after 6 months and 57% after 12
months. These data are similar to those reported by
Buckton et al. (18) for unstable aberrations in irradiated
ankylosing spondylitis patients, thus supporting the the-
ory that MN induced in vivo by ionizing radiation are
mainly derived from acentric chromosome fragments.
Since our initial study, it has been shown that the
CBMN assay can readily detect the in vivo clastogenic
effects of combined radiation (accumulated doses of 10
cGy) and contrastmediainpatientsundergoingexcretory
urography(19).Wells etal. (20) confirmed thatthe CBMN
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assay can, indeed, readily detect exposures in patients
undergoing fractionated partial-body radiotherapy, with
the MN index being directly related to the integral dose.
As a result ofthe possible application ofthe CBMN assay
in biological dosimetry after radiation accidents, several
laboratories around the world have now established the
dose-response parameters after exposure to various
sources of ionizing radiation (3,4,6,7,20-25,29). Further-
more, the Sobel'sparallelogram concept ofriskestimation
(26) is also being implemented to determine the kinetics
and extent ofMN expression using the mouse as a model
(27,28).
Our own data have shown that duringthe 14 days after
whole-body irradiation, the MN frequency in spleen lym-
phocytes declined gradually to approximately half ofthe
value observedimmediatelyafterirradiation. Bycontrast,
the MN frequency in peripheral blood lymphocytes
increasedduringtheweekafterirradiation, butultimately
MN frequencies in the blood and spleen became approx-
imatelythe same byday14 and did not differ significantly
from the MN frequency observed in blood lymphocytes
immediately after exposure (27). Such data suggest that
reliable dose estimates with the CBMN assay can still be
obtained up to 2 weeks after whole body irradiation.
Ithasbeen suggestedthattheapplicationoftheCBMN
assayinbiologicaldosimetryafterradiationaccidentsmay
be compromised by the relatively high background fre-
quency (29,30). However, this criticism is diminished by
the fact that a) it is comparatively easy to determine a
database for baseline MN and define normal population
levels ofMN frequency, and b) exposure levels that are of
clinical importanceinduce farmore MN thanwhat occurs
spontaneously.
Chemicals
The CBMN assayisincreasinglybeingapplied inpopu-
lation studies when significant in vivo exposures to gen-
otoxicchemicals aresuspected. Someofthesestudieshave
been particularly useful, as they have allowed direct com-
parison of the CBMN assay with other cytogenetic end
points. These investigations included occupational expo-
sure to styrene (31,32), chemicals in tannery industries
(33), cyclophosphamide (34), and intervention trials with
paracetamol (35). In three of these studies (32,33,35),
increases in chromatid-type aberrations were reported;
however, there was no corresponding increase in the MN
index.
On the other hand, a recent reportby Osanto et al. (36)
has clearly shown that the CBMN assay can detect chro-
mosomedamageintheperipheralbloodlymphocytesupto
9 years after chemotherapy of patients with testicular
carcinoma. The overall impression that is gained from
these studies is that the CBMN assay may be relatively
insensitive to exposures to chemicals or agents that are
either S-phase dependent or mainly induce covalent
adducts on DNA.
Relative Insensitivity of the CBMN
Assay to Agents That Induce Covalent
DNAAdducts but Not Strand
Breakage
The cytogenetic lesions that are commonlyincreased in
cells that have divided once after in vivo exposure to
S-phase-dependent chemicals are chromatid-type aberra-
tions such as chromatid deletions, achromatic lesions or
gaps, and sister chromatid exchanges (11,37). The molecu-
lar mechanisms responsible for these lesions are not
clearly understood; however, it is generally considered
thatadeletionistheconsequenceofadouble-strandbreak
event,whereas an achromatic lesion orgapmayrepresent
abase damage site or a single-strand break that does not
result in a complete discontinuity in chromosome struc-
ture. As a consequence, ofthe various chemicallyinduced
cytogenetic aberrations, only chromatid or chromosome
deletions canconverttolaggingchromosomefragments at
anaphase and be expressed as a micronucleus. The
possible mechanisms underlying chemicallyinduced DNA
damage and the repair of covalent adducts suggest that
there may be opportunities to improve the conversion of
chemicallyinducedbasedamagetomicronuclei.Anappro-
priatemethodwould enable the conversion ofadduct sites
to single strand breaks in the Go or G1 phase ofthe first
division cycle. Single-strand breaks should convert to
double strand breaks after the first S-phase and, conse-
quently, to chromatid breaks and micronuclei by the time
the first nuclear division is completed. During the past
year, we have concentrated our efforts on developing an
appropriate procedure for this approach.
Conversion of Excision-Repairable
DNA Lesions to Micronuclei Within
One Cell Cycle
The opportunity for enhancing the sensitivity of the
CBMN assay to genotoxins that mainly induce chemical
adducts on DNA has arisen from studies over the last
decade that have shown that cytosine arabinoside (ARA)
cangreatlyenhance induction ofchromosome aberrations
in human lymphocytes after chemical exposure in vitro
(38-40). ARA exerts its effect by inhibiting the DNA
polymerization step (gap filling) that normally occurs
afterexcisionofdamagedbasesduringnucleotideexcision
repair (long-patch repair) or base-excision repair (short-
patch repair) (41,42). As a consequence, excision repair
sites are converted to single-strand breaks. Preston and
Gooch (39) suggested that it is probable that the interac-
tion ofthese breaks, or their conversion to double-strand
breaksafterreplicative DNAsynthesis,couldbethemech-
anism whereby synergistic increments in chromosome
aberrations areproducedbyARAafterexposure tometh-
ylating agents, 4-nitroquinoline-1-oxide, or ionizing radia-
tion. In principle this approach should also enable the
conversion of excision repair sites to MN within one cell
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cycle because acentric chromosome and chromatid frag-
ments are readily converted to MN due to lagging at
anaphase (Fig. 3).
The aim of our approach was therefore to combine the
ARA methodology with the CBMN assay (43). The effect
of ARA on MN induction was determined for human
lymphocytesexposedinvitrotoionizingradiationandtwo
agents that predominantly produced excision-repairable
lesions but were weak inducers of MN in the standard
CBMN assay, namely, methylnitrosourea (MNU) and
ultravoilet light (T, 254 nm). In the protocols used, the
cells were incubated with ARA for most of the G1 phase
after exposure to the genotoxin to ensure that a) the
maximum number of excision sites were converted to
single-strand breaks, and b) to minimize the possibility of
gap-filling after removal ofARA before S-phase started
(Table 1). The induced MN frequencies (i.e., observed
MN frequency in mutagen-treated culture minus MN
IP adduct on DNA
excision of adduct and
inhibition of gap-filling
by ARA results in SSB
- 3.-r_
conversion of SSB to DSB
following replicative DNA
synthesis
frequency in corresponding control) in cultures without
ARA and equivalent cultures treated with ARA were
compared. Theresults (Figs.4-6) showed thatARAtreat-
ment increased the slope of the dose-response curve for
induced MN frequency for X-rays, U, and MNU by a
factor of 1.8, 10.3, and 40.0, respectively. Furthermore, a
24-hr gap between mutagen exposure and the start ofthe
assay did not abolish the increased mutagen sensitivityin
the cultures thatwere also treatedwith ARA, suggesting
that the method would be ofvalue in in vivo monitoring
even when blood samples cannot be obtained immediately
after exposure. Exposure to ARA alone also provides a
toolformonitoringendogenouslyoccurringeventssuchas
excision repair of base hydroxylation due to free-radical
damage.Ourinitialbaselinedataalsosuggestthatthereis
a negative correlation (R = 0.584,p = 0.002) between the
age of donor and the ARA-induced MN frequency in
controlculturesprobablyduetoadeclineinexcisionrepair
with age (43). Thispreliminaryworkclearly suggests that
the combined ARA-CBMN assay can considerably
improve the role of the micronucleus assay in biological
dosimetryand screeningofnewchemicalsintroducedinto
the environment. However, due to its inherent sensitivity
anduntilwe canbetterunderstandthepossible confound-
ingfactors influencing interindividual variability in ARA-
induced MN, itwould seemprudent, atthis earlystage, to
limit the application ofthe combined ARA-CBMN assay
only to those studies where individuals can act as their
own controls.
DSB expressed as
chromatid break
lagging chromatid break
5. ( @ ) expressed as micronucleus
FIGURE 3.Aschematic diagram explaining apossible mechanism forthe
conversion by cytosine arabinoside of an excision-repairable DNA lesion
to a micronucleus within one cell cycle. SSB, single-strand break; DSB,
double-strand break; ARA, cytosine arabinoside.
Table 1. Protocol for the conversion ofexcision-repairable
DNA lesions to micronuclei within one cell cycle
in human lymphocytes.
0 hr 16 hr 44 hr 72 hr
1. Stimulate 3. Wash 2X 5. Add CYT-B 6. Harvest
with PHA with HBSS cells
2. Add ARA 4. Iransfer to
(control fresh
without medium +
ARA) CM + DC
Abbreviations: PHA, phytohemagglutinin; ARA, cytosine arabinoside
at 1 ,ug/,uL; HBSS, Hanks' balanced salt solution; CM, conditioned
medium as a source of interleukin-2; DC, deoxycytidine at 10 ,ug/mL;
CYT-B, cytochalasin-B.
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FIGURE 4. X-ray induction of micronuclei in cultures without cytosine
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FIGURE 5. Methyl nitrosourea induction of micronuclei in cultures
withoutARA( -ARA) andcultureswithARA( +ARA). Thevertical line
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Protocol A
30o *
'U
C.)
20
WI 200 - * -EARA
zu * * ^ * +ARA
z
(, 100"
0
6o 120 180
UV DOSE (ergs/square mm)
FIGUJRE 6. UV induction of micronuclei in cultures without cytosine
arabinoside (-ARA) and cultures with ARA (+ARA). It was not
possible todetermine themicronucleifrequencyin +ARAcultures atthe
highest UVdosebecausethiscombination madeallthecellsnecrotic. The
vertical linesrepresenttheSE ofthemean (*p < 0.01, **p < 0.06, n = 3).
Conclusion
Since the initial description of the CBMN assay, there
have been several reports that have enabled a better
definition of its potential for biological dosimetry. The
general consensus seems that the CBMN assay, due to its
relative ease of implementation and its ability to comple-
ment other cytogenetic assays, has an important role to
play in biomonitoring genotoxic exposure. However, there
also appears to be some concern that the baseline MN
frequencyin human populations requires better definition
if this technique is to effectively discriminate between
DNA damage occurring as a result of normal metabolic
processes and genotoxic effects due to man-made or natu-
ral environmental agents. Our most recent investigations
indicate that it is possible to markedly increase the sen-
sitivity of the CBMN assay to genotoxins that mainly
induce excision-repairable lesions (43), and Norman et al.
(44) have recently demonstrated that the cytokinesis-
block methodology can also be implemented to readily
quantify HPRT variants, thus enhancing the role of this
technique in mutagenesis research. Finally, one can look
forward to further development of automation by image
analysis (45), which should enhance the application ofthe
micronucleus assayinroutine screeningprograms such as
assessment ofinterindividual variation in radiosensitivity
(46), prediction of radiocurability of tumors (47-50), and
generally in those studies of a molecular epidemiological
design (2) that would require several hundred blood sam-
ples to be cultured for micronucleus measurement.
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